Literature DB >> 683097

Synergism between tetracycline and amphotericin B in experimental amoebic meningoencephalitis.

Y H Thong, B Rowan-Kelly, C Shepherd, A Ferrante.   

Abstract

The efficacy of tetracycline and amphotericin B in the treatment of primary amoebic meningoencephalitis was studied by means of a mouse model. The results showed marked synergism between these two drugs. Mice who recieved 50 microgram amphotericin B daily succumbed to the infection with only 28.6% survival compared to 0% in untreated controls. In contrast, survival percentage was increased to 66.7% and 84.6% in mice receiving the combined dosage schedule of 50 microgram amphotericin B with 2 tetracycline, and 50 microgram amphotericin B with 3 mg tetracycline, respectively. The finding of synergism between tetracycline and amphotericin may provide a better means for the treatment of this disease.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 683097

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  4 in total

1.  Synergistic activities of azithromycin and amphotericin B against Naegleria fowleri in vitro and in a mouse model of primary amebic meningoencephalitis.

Authors:  Shannon M Soltow; George M Brenner
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

2.  In vitro susceptibilities of Naegleria fowleri strain HB-1 to selected antimicrobial agents, singly and in combination.

Authors:  K K Lee; S L Karr; M M Wong; P D Hoeprich
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

3.  Effect of tetracycline treatment on immunological responses in mice.

Authors:  Y H Thong; A Ferrante
Journal:  Clin Exp Immunol       Date:  1980-03       Impact factor: 4.330

4.  Enhancement of the in vitro activity of amphotericin B against Aspergillus spp. by tetracycline analogs.

Authors:  C E Hughes; C Harris; L R Peterson; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.